Form 4 for ERNA Ernexa Therapeutics Inc.
Accepted 2025-04-04 00:00:00 ET · period of report 2025-04-02 · accession 0001104659-25-032060 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-04-04 | 2025-04-02 | ERNA | Cherington Charles | 10% | P - Purchase | $0.1 | +3.77M | 20.40M | +23% | +$376.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-04-02 | P | A | 3,768,397 | $0.1 | 20,401,602 | D | — | — | (F1) On April 2, 2025, pursuant to a private placement offering by the Issuer, the reporting person acquired 3,768,397 shares of the Issuer's Common Stock. (F2) On December 3, 2024, the Issuer paid a dividend to all holders of record of its Series A Preferred Stock on such date of $0.05 per share of Series A Preferred Stock. Pursuant to the terms of the Series A Preferred Stock, the Issuer elected to pay the dividend in an equivalent amount of common stock. As a result, the Reporting Person received 5,082 shares of the Issuer's common stock. |